A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients

NCT ID: NCT06021041

Last Updated: 2023-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-13

Study Completion Date

2024-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective clinical study to analyze the clinical characteristics, complications, and effects of different treatment options on long-term prognosis of severe tuberculosis patients. All cases of severe tuberculosis diagnosed between 2016 and 2021 were included in the electronic medical record system of one center, and data such as demographics, hospitalization information, clinical information, laboratory or imaging examinations, treatment plans, and outcomes were collected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. For patients with severe pulmonary tuberculosis, imaging and grading diagnosis meet any of the following:

1. Damaged lung ≥ 1 lobe
2. Chest CT shows lesions in ≥3 lung lobes
3. Hematogenous disseminated pulmonary tuberculosis
4. caseous pneumonia
5. bronchial tuberculosis
6. Multiple hilar or mediastinal lymph node enlargement in primary pulmonary tuberculosis
7. Rifampicin-resistant, multidrug-resistant, polydrug-resistant or pan-drug-resistant tuberculosis
8. Combined more than 2 cavities over 8mm
9. Tuberculous massive hemoptysis
10. Pulmonary tuberculosis complicated with acute infection (including multidrug-resistant bacterial infection, fungal infection or multiple infection)
11. Combined with extrapulmonary tuberculosis

* Intracranial tuberculosis, spinal cord and/or meningeal tuberculosis
* Pleural effusion, pericardial effusion

* Empyema or empyema, hemopneumothorax, tracheobronchopleural fistula and severe infection.
* Heart failure caused by cardiac tamponade or constrictive pericarditis
* Multiple sites of lymphatic tuberculosis or surgery is necessary

* Cervical lymphatic tuberculosis
* Mediastinal lymphatic tuberculosis
* Abdominal or retroperitoneal lymph node tuberculosis
* Abdominal tuberculosis, tuberculous peritonitis (ascites or multiple serous cavities)

* Intestinal tuberculosis causes complete or incomplete intestinal root obstruction or perforation or massive bleeding or severe abdominal infection
* Gastrointestinal hemorrhage caused by tuberculosis of the digestive system, etc.
* Musculoskeletal tuberculosis

* Spinal (cervical, thoracic, lumbar, sacral) tuberculosis
* Bones in other parts
* Merge surrounding abscess
* Urinary or renal tuberculosis

* Renal failure or damaged blood vessels caused by renal tuberculosis
* Ureteral stenosis or blockage caused by urinary tuberculosis
* Adrenal tuberculosis in hypoadrenal insufficiency
* Liver tuberculosis
2. Age and gender are not limited.

Exclusion Criteria

* Patients with no clear diagnosis at discharge.
* Patients judged by the investigator to be unsuitable for inclusion in this protocol.
* The discharge diagnosis was central nervous system tuberculosis, or tuberculous meningitis, or tuberculous cerebrospinal meningitis, or tuberculous meningoencephalitis, or tuberculous encephalitis, or tuberculous brain abscess, or spinal tuberculosis, or tuberculous Hydrocephalus, and is currently participating in other clinical studies.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tongji Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Qin Ning

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status

Wuhan Pulmonary Hospital(Wuhan Institute for Tuberculosis Control)

Hubei, Wuhan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RETUBO-S

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ultra-Short Regimen for Elderly DS-TB
NCT07076225 NOT_YET_RECRUITING PHASE3
Post TB Sequelae Study
NCT06744179 ENROLLING_BY_INVITATION